drugset
drugset / Trial / NCT03837626

ENAC Blockade and Arterial Stiffness

NCT03837626 ↗

Phase 2/3 Completed 137 enrolled University of Missouri-Columbia
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.

Timeline

Start
2019-07-15
Primary completion
2024-10-05
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amiloride Small molecule 5 mg —

Indications

No indication recorded.